<?xml version='1.0' encoding='utf-8'?>
<document id="29357810"><sentence text="Cytochrome P450 1A2 Messenger RNA is a More Reliable Marker than Cytochrome P450 1A2 Activity, Phenacetin O-Deethylation, for Assessment of Induction Potential of Drug-Metabolizing Enzymes Using HepaRG Cells."><entity charOffset="95-105" id="DDI-PubMed.29357810.s1.e0" text="Phenacetin" /></sentence><sentence text="The HepaRG cells have key drug metabolism functionalities comparable to those of primary human hepatocytes" /><sentence text=" Many studies have reported that this cell line can be used as a reliable in vitro model for human drug metabolism studies, including the assessment of cytochrome P450 (CYP) induction" /><sentence text="" /><sentence text="The objective of this study is to determine whether CYP mRNA level measurement is superior to the CYP enzyme activity measurement as a convenient high-throughput method for evaluating CYP induction potential using HepaRG cells" /><sentence text="" /><sentence text="QuantiGene Plex 2" /><sentence text="0 Assay and LC/MS/MS" /><sentence text=" mRNA expression levels and enzyme activities of CYP1A2, CYP2B6, and CYP3A in HepaRG cells treated with prototypical inducers of each CYP isoform [omeprazole (OME) for CYP1A2, phenobarbital (PB) for CYP2B6, and rifampicin (RIF) for CYP3A] were evaluated"><entity charOffset="159-162" id="DDI-PubMed.29357810.s9.e0" text="OME" /><entity charOffset="176-189" id="DDI-PubMed.29357810.s9.e1" text="phenobarbital" /><entity charOffset="191-193" id="DDI-PubMed.29357810.s9.e2" text="PB" /><entity charOffset="199-205" id="DDI-PubMed.29357810.s9.e3" text="CYP2B6" /><entity charOffset="211-221" id="DDI-PubMed.29357810.s9.e4" text="rifampicin" /><entity charOffset="223-226" id="DDI-PubMed.29357810.s9.e5" text="RIF" /><pair ddi="false" e1="DDI-PubMed.29357810.s9.e0" e2="DDI-PubMed.29357810.s9.e0" /><pair ddi="false" e1="DDI-PubMed.29357810.s9.e0" e2="DDI-PubMed.29357810.s9.e1" /><pair ddi="false" e1="DDI-PubMed.29357810.s9.e0" e2="DDI-PubMed.29357810.s9.e2" /><pair ddi="false" e1="DDI-PubMed.29357810.s9.e0" e2="DDI-PubMed.29357810.s9.e3" /><pair ddi="false" e1="DDI-PubMed.29357810.s9.e0" e2="DDI-PubMed.29357810.s9.e4" /><pair ddi="false" e1="DDI-PubMed.29357810.s9.e0" e2="DDI-PubMed.29357810.s9.e5" /><pair ddi="false" e1="DDI-PubMed.29357810.s9.e1" e2="DDI-PubMed.29357810.s9.e1" /><pair ddi="false" e1="DDI-PubMed.29357810.s9.e1" e2="DDI-PubMed.29357810.s9.e2" /><pair ddi="false" e1="DDI-PubMed.29357810.s9.e1" e2="DDI-PubMed.29357810.s9.e3" /><pair ddi="false" e1="DDI-PubMed.29357810.s9.e1" e2="DDI-PubMed.29357810.s9.e4" /><pair ddi="false" e1="DDI-PubMed.29357810.s9.e1" e2="DDI-PubMed.29357810.s9.e5" /><pair ddi="false" e1="DDI-PubMed.29357810.s9.e2" e2="DDI-PubMed.29357810.s9.e2" /><pair ddi="false" e1="DDI-PubMed.29357810.s9.e2" e2="DDI-PubMed.29357810.s9.e3" /><pair ddi="false" e1="DDI-PubMed.29357810.s9.e2" e2="DDI-PubMed.29357810.s9.e4" /><pair ddi="false" e1="DDI-PubMed.29357810.s9.e2" e2="DDI-PubMed.29357810.s9.e5" /><pair ddi="false" e1="DDI-PubMed.29357810.s9.e3" e2="DDI-PubMed.29357810.s9.e3" /><pair ddi="false" e1="DDI-PubMed.29357810.s9.e3" e2="DDI-PubMed.29357810.s9.e4" /><pair ddi="false" e1="DDI-PubMed.29357810.s9.e3" e2="DDI-PubMed.29357810.s9.e5" /><pair ddi="false" e1="DDI-PubMed.29357810.s9.e4" e2="DDI-PubMed.29357810.s9.e4" /><pair ddi="false" e1="DDI-PubMed.29357810.s9.e4" e2="DDI-PubMed.29357810.s9.e5" /></sentence><sentence text="" /><sentence text="Although the activities of CYP2B6 and CYP3A were induced by treatment with PB and RIF, we found that the activity of phenacetin O-deethylase (PHOD), which is known as a marker of the activity of CYP1A2, was also enhanced by treatment with these non-CYP1A2 inducers in HepaRG cells"><entity charOffset="117-127" id="DDI-PubMed.29357810.s11.e0" text="phenacetin" /><entity charOffset="75-84" id="DDI-PubMed.29357810.s11.e1" text="PB" /><entity charOffset="82-91" id="DDI-PubMed.29357810.s11.e2" text="RIF" /><pair ddi="false" e1="DDI-PubMed.29357810.s11.e1" e2="DDI-PubMed.29357810.s11.e1" /><pair ddi="false" e1="DDI-PubMed.29357810.s11.e1" e2="DDI-PubMed.29357810.s11.e2" /><pair ddi="false" e1="DDI-PubMed.29357810.s11.e1" e2="DDI-PubMed.29357810.s11.e0" /><pair ddi="false" e1="DDI-PubMed.29357810.s11.e2" e2="DDI-PubMed.29357810.s11.e2" /><pair ddi="false" e1="DDI-PubMed.29357810.s11.e2" e2="DDI-PubMed.29357810.s11.e0" /></sentence><sentence text=" Based on previously published reports, we hypothesized that the expression ratio of CYP3A to CYP1A2 is much higher in HepaRG cells than in human hepatocytes; this may result in a nonnegligible contribution of CYP3A to the PHOD reaction in HepaRG cells" /><sentence text=" Studies using CYP3A inhibitor and pregnane X receptor-knockout HepaRG cells supported this hypothesis" /><sentence text="" /><sentence text="The measurement of mRNA serves as a higher reliable indicator for the evaluation of CYP induction potential when using HepaRG cells" /><sentence text="" /></document>